Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disorders.

Davidson DC, Hirschman MP, Sun A, Singh MV, Kasischke K, Maggirwar SB.

PLoS One. 2012;7(12):e51793. doi: 10.1371/journal.pone.0051793. Epub 2012 Dec 12.

2.

Modeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier Dysfunction.

Jones LD, Jackson JW, Maggirwar SB.

PLoS One. 2016 Mar 17;11(3):e0151702. doi: 10.1371/journal.pone.0151702. eCollection 2016.

3.

Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.

Davidson DC, Schifitto G, Maggirwar SB.

PLoS One. 2013;8(3):e59950. doi: 10.1371/journal.pone.0059950. Epub 2013 Mar 28.

4.

Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals.

Davidson DC, Hirschman MP, Spinelli SL, Morrell CN, Schifitto G, Phipps RP, Maggirwar SB.

J Immunol. 2011 Jan 1;186(1):584-91. doi: 10.4049/jimmunol.1001911. Epub 2010 Nov 29.

5.
6.

Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis.

Ramirez SH, Fan S, Dykstra H, Reichenbach N, Del Valle L, Potula R, Phipps RP, Maggirwar SB, Persidsky Y.

J Neurosci. 2010 Jul 14;30(28):9454-64. doi: 10.1523/JNEUROSCI.5796-09.2010.

7.

Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder.

Gandhi N, Saiyed ZM, Napuri J, Samikkannu T, Reddy PV, Agudelo M, Khatavkar P, Saxena SK, Nair MP.

J Neurovirol. 2010 Jul;16(4):294-305. doi: 10.3109/13550284.2010.499891.

PMID:
20624003
8.

Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia.

Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S, Maggirwar SB.

J Immunol. 2007 Mar 1;178(5):3226-36.

9.

Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?

Davidson DC, Jackson JW, Maggirwar SB.

J Neuroinflammation. 2013 Dec 1;10:144. doi: 10.1186/1742-2094-10-144. Review.

10.

Differential effects of Tat proteins derived from HIV-1 subtypes B and recombinant CRF02_AG on human brain microvascular endothelial cells: implications for blood-brain barrier dysfunction.

Woollard SM, Bhargavan B, Yu F, Kanmogne GD.

J Cereb Blood Flow Metab. 2014 Jun;34(6):1047-59. doi: 10.1038/jcbfm.2014.54. Epub 2014 Mar 26.

11.

Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability.

Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Fernandez SF, Chawda R, Shanahan TC, Schwartz SA.

J Clin Immunol. 2008 Sep;28(5):528-41. doi: 10.1007/s10875-008-9208-1. Epub 2008 Jun 24.

PMID:
18574677
12.

HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain.

Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, Toborek M.

Mol Cell Neurosci. 2003 Sep;24(1):224-37.

PMID:
14550782
13.

HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia.

Wang J, Zhang W, Nardi MA, Li Z.

J Thromb Haemost. 2011 Mar;9(3):562-73. doi: 10.1111/j.1538-7836.2010.04168.x.

14.

HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9.

Xu R, Feng X, Xie X, Zhang J, Wu D, Xu L.

Brain Res. 2012 Feb 3;1436:13-9. doi: 10.1016/j.brainres.2011.11.052. Epub 2011 Dec 7.

PMID:
22197032
15.
16.

Characterization of platelet-monocyte complexes in HIV-1-infected individuals: possible role in HIV-associated neuroinflammation.

Singh MV, Davidson DC, Jackson JW, Singh VB, Silva J, Ramirez SH, Maggirwar SB.

J Immunol. 2014 May 15;192(10):4674-84. doi: 10.4049/jimmunol.1302318. Epub 2014 Apr 11.

17.

HIV-1 Tat triggers nuclear localization of ZO-1 via Rho signaling and cAMP response element-binding protein activation.

Zhong Y, Zhang B, Eum SY, Toborek M.

J Neurosci. 2012 Jan 4;32(1):143-50. doi: 10.1523/JNEUROSCI.4266-11.2012.

18.

HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier.

Hayashi K, Pu H, Andras IE, Eum SY, Yamauchi A, Hennig B, Toborek M.

J Cereb Blood Flow Metab. 2006 Aug;26(8):1052-65. Epub 2005 Dec 14.

PMID:
16395283
19.

Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins.

Cooper I, Sasson K, Teichberg VI, Schnaider-Beeri M, Fridkin M, Shechter Y.

J Biol Chem. 2012 Dec 28;287(53):44676-83. doi: 10.1074/jbc.M112.395384. Epub 2012 Nov 13.

20.

Permeability of the blood-brain barrier to HIV-1 Tat.

Banks WA, Robinson SM, Nath A.

Exp Neurol. 2005 May;193(1):218-27.

PMID:
15817280

Supplemental Content

Support Center